Company Profile

BioAtla LLC
Profile last edited on: 2/16/2023      CAGE: 66RX2      UEI: UU5NYJWUKTG4

Business Identifier: Conditionally Active Biologic (CAB) antibody therapeutics
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

11085 Torreyana Road
San Diego, CA 92121
   (858) 558-0708
Location: Multiple
Congr. District: 52
County: San Diego

Public Profile

Employing a proprietary next-generation antibody discovery and evolution platform, BioAtla LLC is described as a protein therapeutic company developing safer, more effective cancer drugs - novel monoclonal antibody and cell-based therapeutics. The firm's Conditionally Active Biologics (CAB) and Comprehensive Integrated Antibody Optimization (CIAO!) platforms - reported as protected by more than 150 issued patents and patent applications - enables the development of novel biologics (CABs) that have the characteristics of more selective targeting of cancer tissue and improved manufacturability. Improved selectivity for the tumor microenvironment - even when target is also found in normal tissue - not only improves safety but also expands the universe of potential drug targets, enabling the treatment of previously untreatable cancers. In January 2022, BioAtla announced a Clinical Collaboration with Bristol Myers Squibb to study Mecbotamab Vedotin (BA3011) and Ozuriftamab Vedotin (BA3021) in combination with Opdivo® (nivolumab) for treatment of solid tumors

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Key People / Management

  Jay M Short -- Chairman, Chief Executive Officer, President & Cofounder

  William Boyle -- Vice President of Translational Medicine

  Neil Gibson -- Senior Vice President & Chief Development Officer

  Carolyn Anderson Short -- Chief of Intellectual Property & Strategy, Cofounder

  Richard Waldron -- Chief Financial Officer